Vaccine, drug manufacturing startup secures angel funding > Spokane Journal of Business
Summary
Meanwhile, the company is considering how the current coronavirus pandemic could affect the construction time line for its planned $30 million West Plains manufacturing facility, which will produce sterile drug products, including injectable vaccines. Patrick Haffey, CEO of Selkirk Pharma, declines to discuss the latest round of funding. “The situation is so dynamic that we’re talking to all of our trade partners (and) permitting authorities to see how the project is going to be impacted,” Haffey says. As first reported by the Journal last summer, Selkirk Pharma plans to build a 63,000-square-foot manufacturing facility on more than 6 acres of land at 9110 W. Granite, in the Pacific Northwest Technology Park, in Airway Heights. According to proprietary market data software subscription platform PitchBook, the 3-year-old company headquartered at 827 W. First, in downtown Spokane, previously had received $1.73 million in angel funding in March 2018.